Top

Published in:

01-02-2010 | Medical Oncology

Caution in Adding Bevacizumab in the Adjuvant Treatment of Breast Cancer

Authors: Dimosthenis Ziogas, MD, Dimitrios Roukos, MD

Published in: Annals of Surgical Oncology | Issue 2/2010

Excerpt

The strategic decision to integrate antiangiogenic agents in the treatment of solid cancers has now become controversial. New preclinical data and clinical trials results have raised questions about the potential harm derived from the administration of the antiangiogenic agent bevacizumab in both clinical practice in the setting of metastatic disease and in clinical trials research in the adjuvant setting.1 …

Ellis LM, Reardon DA. Cancer: the nuances of therapy. Nature 2009;458(7236):290–2.CrossRefPubMed

Bahri S, Chen JH, Mehta RS, et al. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol. 2009;16:1619–28.CrossRefPubMed

Roukos DH. Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn. 2009;9:217–21.CrossRefPubMed

Roukos DH. Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn. 2009;9:227–9.CrossRefPubMed

Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol. 2009;16:772–3.CrossRefPubMed

Roukos DH, Tzakos A, Zografos G. Current concerns and challenges towards tailored antiangiogenic therapy in cancer. Expert Rev Anticancer Ther. 2009;9(10):1413–6.CrossRefPubMed

Roukos DH. Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg. 2009;249(6):1067–8.CrossRefPubMed

Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol. 2009;16(7):1771–82.CrossRefPubMed

Roukos DH. Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther. 2009;9(4):389–92.CrossRefPubMed

10.

Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol. 2009;27(8):1337–8.CrossRefPubMed

11.

Roukos DH. Radiation therapy for breast cancer. N Engl J Med. 2009;360(13):1362; author reply 1363.CrossRefPubMed

Title: Caution in Adding Bevacizumab in the Adjuvant Treatment of Breast Cancer
Authors: Dimosthenis Ziogas, MD
Dimitrios Roukos, MD
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 2/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-009-0798-5

At a glance: The STEP trials

Springer Medicine

Caution in Adding Bevacizumab in the Adjuvant Treatment of Breast Cancer

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2010

Erratum to: Axillary Recurrence Rate Following Negative Sentinel Node Biopsy for Invasive Breast Cancer: Long-Term Follow-Up

National Quality Measures for Breast Centers (NQMBC): A Robust Quality Tool

In Reply: Cost Effectiveness of Staging Procedures in Patients with Stage I/II Melanoma

Temporary Placement of Self-Expanding Oesophageal Stents as Bridging for Neo-Adjuvant Therapy

The Lymph Node Ratio Staging System in Gastric Cancer

Reevaluation of the Locoregional Recurrence Rate in Melanoma Patients With a Positive Sentinel Node Compared to Patients With Palpable Nodal Involvement